Autogenous Vaccine Market

Autogenous Vaccine Market Study by Bacterial Strain and Virus Strain for Veterinary Research Institutes, Livestock Farming Companies, and Veterinary Clinics & Hospitals from 2024 to 2034

Analysis of Autogenous Vaccine Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Autogenous Vaccine Market Outlook (2024 to 2034)

As per Fact.MR’s new market research report, the global autogenous vaccine market is estimated to be valued at US$ 144.8 million in 2024. Worldwide demand for autogenous vaccines is forecasted to increase at 5.5% CAGR and reach a market value of US$ 246.8 million by the end of 2034.

Autogenous vaccines are specially developed to address some particular pathogens or diseases present within a certain animal group or in a particular region. There is a growing demand for customized solutions to address diseases, which are not efficiently covered through conventional vaccines. Further, increasing awareness about the importance of animal welfare and health among veterinarians, regulatory bodies, and farmers is projected to generate requirements for tailored and effective solutions to combat different diseases affecting animals.

Significant expansion of the livestock sector is forecasted to boost demand for autogenous vaccines. With increasing demand for animal-derived products, there is a parallel requirement to ensure the well-being and health of livestock, which is generating demand for customized vaccines. Increasing regulatory pressure and concerns about antibiotic resistance to minimize their use in livestock are projected to lead to rising interest in alternative strategies for disease management, which include vaccines as a safer option.

  • Demand for autogenous vaccines in China is forecasted to increase at 4.3% CAGR and reach a valuation of US$ 5 million by the end of 2034.
  • North America is projected to account for 34.8% of the global autogenous vaccine market share by 2034.
  • Livestock farming companies are forecasted to account for 45.3% share of global market revenue by 2034.

Regulatory bodies in many countries are forecasted to show support and flexibility for the approval of autogenous vaccines owing to an increasing understanding of their importance in addressing specific diseases in animals. Furthermore, outbreaks of animal diseases, particularly with economic impacts, are projected to increase the requirements for targeted and rapid responses, therefore positively contributing to the expansion of the autogenous vaccine market size.

Report Attributes Details
Autogenous Vaccine Market Size (2024E) US$ 144.8 Million
Forecasted Market Value (2034F) US$ 246.8 Million
Global Market Growth Rate (2024 to 2034) 5.5% CAGR
United States Market Share (2034F) 93.6%
Bacteria Strains Segment Market Share (2034F) 71%
Mexico Market Growth Rate (2024 to 2034) 4.6% CAGR
Key Companies Profiled
  • Newport Laboratories, Inc.
  • Ceva
  • Elanco Animal Health
  • ACE Laboratory Services
  • AniCon Labor GmbH
  • Huvepharma, Inc.
  • Cambridge Technologies
  • Dyntec s. r. o.
  • Vaxxinova
  • Hygieia Biological Laboratories
  • Sanphar
  • Addison Biological Laboratory
  • Kennebec River Biosciences
  • Barramundi Asia Pte Ltd.

Don't Need a Global Report?

save 40%! on Country & Region specific reports

Which Key Factors are Positively Influencing Autogenous Vaccine Market Growth?

“Growing Demand for Autogenous Vaccines for Livestock Management”

In recent times, there has been a growing demand to enhance animal husbandry practices. In addition, growing emphasis is given to minimizing the use of antibiotics for the treatment of sick herds or animals with increasing public interest in animal health and welfare. Further, many developed countries are emphasizing minimizing the use of antibiotics to reduce animal loss.

Owing to the limited availability of some veterinary medicines, it is difficult to manage health issues for some species, especially minor ones such as the turkey. Thus, demand for accessible products, such as autogenous vaccines, is projected to rise in the coming 10 years.

“Focus on Production of Customized Autogenous Vaccines”

Encountering constant changes and evolution in reoviruses is common. Various serotypes are harmful to the health and performance of poultry. Therefore, several manufacturers are emphasizing the production of customized autogenous poultry reovirus vaccines. Farm-specific setups are included in these vaccines to ensure a close match for the constantly changing environment of the farms. Autogenous vaccinations are recognized as an efficient approach to addressing antigenic changes in the fields.

For instance :

  • In April 2020, Phibro Animal Health Company added antigen combinations to its available range of autogenous vaccines. These customized and advanced vaccines are projected to assist poultry farmers in protecting their animals against several infectious diseases.

What are Market Players Focusing on to Remain Competitive?

“Stringent Regulatory Framework for Production and Export of Vaccines”

Autogenous vaccines are specialized vaccinations, which are produced from antigens. Therefore, a licensed facility is pivotal in this regard. In addition, there are differences in the regulatory laws among countries. Every country has its license regulations and requirements for vaccine production. Therefore, an absence of set uniform regulations is projected to adversely impact autogenous vaccine market growth.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Why are Startups Invest in This Business?

“Production of Customized Vaccines Leveraging Advancements in Biotechnology”

Advancements taking place in molecular biology and biotechnology are estimated to facilitate the development of more efficient autogenous vaccines. Several techniques, including proteomics, bioinformatics, and genomics are forecasted to play a pivotal role in the development and production of these customized vaccines, which are further projected to attract startups to invest in the market.

Country-wise Insights

North America is forecasted to hold 34.8% of the global market share by 2034 owing to the rising incidences of livestock-related diseases, including otitis externa, sinusitis, pharyngitis, and dermatitis. Further, the growing use of customized vaccines to treat these diseases is projected to contribute to autogenous vaccine market trends.

Why is the United States Garnering the Attention of Players?

“Supportive Government Initiatives for Veterinary Care”

Attribute United States
Market Value (2024E) US$ 50 Million
Growth Rate (2024 to 2034) 4.9% CAGR
Projected Value (2034F) US$ 80 Million

The United States is forecasted to hold 93.6% share of the North American market by 2034. Farmers in the United States are made aware of the impact of livestock diseases along with their preventive measures through government programs and initiatives.

Public health officials, manufacturers, the USDA’s ARS (Animal Research Service), etc., work together for conducting surveillance programs for advancing scientific studies to address issues of public and veterinary health. These campaigns are projected to increase awareness about animal health, therefore contributing to the rising demand for autogenous vaccines.

Why are Suppliers of Autogenous Vaccines Interested in China?

“Increasing Use of Animal Vaccines amid Rising Incidence of Livestock-Related Diseases”

Attribute China
Market Value (2024E) US$ 4 Million
Growth Rate (2024 to 2034) 4.3% CAGR
Projected Value (2034F) US$ 5 Million

China is projected to occupy 89.4% share of the East Asia market by 2034. Increasing incidences of livestock-related diseases in the country along with the growing use of animal vaccines is forecasted to positively impact consumption of autogenous vaccines, therefore contributing to market growth.

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Category-wise Insights

Fact.MR, through its newly published study, asserts that traction for bacterial strains is projected to increase further owing to their higher stability cultures in incubators and in vitro labs. In addition, the built-in adjuvant qualities of these strains are also projected to contribute to their increased demand.

Which Type of Autogenous Vaccines are Preferred for Livestock Disease Management?

“Widespread Adoption of Bacterial Vaccines Due to More Efficient Oral Administration Options”

Attribute Bacterial Strain
Segment Value (2024E) US$ 98.7 Million
Growth Rate (2024 to 2034) 5.9% CAGR
Projected Value (2034F) US$ 175.2 Million

Bacterial strains are projected to hold 71% share of the global market by 2034, as per the research analysis published by Fact.MR, a market research and competitive intelligence provider. Live bacterial vaccines offer multiple benefits, including built-in adjuvant qualities, the ability to replace real infection, and more efficient oral administration options. Thus, these benefits are projected to generate demand for bacterial strains for the development of customized autogenous vaccines.

What is the Contribution of Livestock Farming Companies to the Global Market?

“High Demand for Animal Products Driving Substantial Autogenous Vaccine Use by Livestock Companies”

Attribute Livestock Farming Companies
Segment Value (2024E) US$ 68.8 Million
Growth Rate (2024 to 2034) 5% CAGR
Projected Value (2034F) US$ 111.8 Million

Livestock farming companies are forecasted to account for 45.3% share of global market revenue by 2034, according to the analysis published by Fact.MR. The livestock sector is very active around the world. Significant transformations in the livestock sector in potentially high-growth markets are attributed to the increasing demand for various types of animal products. Growing urbanization, income, and human population are projected to increase the consumption of livestock products, thus driving market growth.

Competitive Landscape

Presence of regional and global players is making the market highly competitive. Market players are emphasizing inorganic expansion as one of the prominent growth strategies to maintain competitiveness. Expenditures for the strengthening of the supply chain management system, offering quality products, new developments, etc., are set to help companies secure their position. In addition, participants are also working to increase their reach across regions through acquisitions, mergers, etc.

For instance :

  • Ceva Sante Animale, in September 2020, tripled its capability for autogenous vaccine production at its French facility.

Key players in the autogenous vaccine market are Newport Laboratories, Inc., Ceva, Elanco Animal Health, ACE Laboratory Services, AniCon Labor GmbH, Huvepharma, Inc., Cambridge Technologies, Dyntec s. r. o., Vaxxinova, Hygieia Biological Laboratories, Sanphar, Addison Biological Laboratory, Kennebec River Biosciences, and Barramundi Asia Pte Ltd.

Segmentation of Autogenous Vaccine Market Research

  • By Product Type :

    • Bacterial Strain
    • Virus Strain
  • By End User :

    • Veterinary Research Institutes
    • Livestock Farming Companies
    • Veterinary Clinics & Hospitals
  • By Region :

    • North America
    • Europe
    • East Asia
    • Latin America
    • Middle East & Africa
    • South Asia & Oceania

- FAQs -

What is the valuation of the autogenous vaccine market in 2024?

The global autogenous vaccine market is estimated at US$ 144.8 million in 2024.

What is the sales projection for autogenous vaccines for 2034?

Sales of autogenous vaccines are projected to reach US$ 246.8 million by the end of 2034.

At what rate is the demand for autogenous vaccines projected to grow?

Demand for autologous vaccines is forecasted to increase at 5.5% CAGR from 2024 to 2034.

How much share of the global market is North America projected to account for?

North America is projected to hold 34.8% share of global market revenue by 2034.

At what rate are the sales of autogenous vaccines forecasted to rise in Mexico?

Sales of autogenous vaccines in Mexico are forecasted to increase at a CAGR of 4.6% from 2024 to 2034.

What is an autogenous vaccine for humans?

Autogenous vaccines are used to treat chronic infections, including respiratory tract infections, skin infections, urinary tract infections, and colon infections.

- Also of Interest -

Vaccine Management Solution Market

Vaccine Management Solution Market By Component (Solutions, Services), By Model (Platform, One-point), By Subscription (New, Renew), By End Use (Public, Private) & By Region - Global Market Insights 2022-2032

Flu Vaccine Market

Flu Vaccine Market Study by Trivalent Flu Vaccines and Quadrivalent Flu Vaccines in Intramuscular Injections, Nasal Sprays, and Intradermal Shots from 2024 to 2034

Respiratory Virus Vaccines Market

Respiratory Virus Vaccines Market Analysis by Inactivated/Killed, Live-attenuated, and Recombinant for Influenza, Measles, Mumps, & Rubella, and Coronavirus Disease (COVID-19) from 2023 to 2033

Vaccine Adjuvants Market

Vaccine Adjuvants Market Analysis by Adjuvant Emulsions, Pathogen Components, Saponin-based Adjuvants, Particulate Adjuvants, and Other Products from 2023 to 2033

Autogenous Vaccine Market

Schedule a Call